Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma
Abstract
We used the bortezomib (velcade) plus MP (VMP) in 24 previously untreated patients with multiple myeloma (MM). The patients had a median age of 73 years (range, 65–83 years). For patients who received velcade plus MP the overall response rate was 62.4 %. 33.2 % patients achieved complete remission (CR+n-CR). The median duration of the CR was 10.3 months. Side effects were predictable and manageable. The most common adverse events reported were asthenia, neuropathy, neutropenia and anemia. Serious adverse events were rare. These results establish VMP as a new standard of care in elderly untreated patients with multiple myeloma. VMP is highly active and well tolerated in elderly patients (> 75 years) with newly diagnosed multiple myeloma.
About the Authors
S. S. Bessmeltsev
Russian Research Institute of Hematology and Transfusiology
Russian Federation
Russian Federation
St.-Petersburg
L. V. Stelmashenko
Russian Research Institute of Hematology and Transfusiology
Russian Federation
Russian Federation
St.-Petersburg
N. V. Stepanova
St.-Petersburg State Pavlov Medical University
Russian Federation
Russian Federation
St.-Petersburg
K. M. Abdulkadyrov
Russian Research Institute of Hematology and Transfusiology
Russian Federation
Russian Federation
St.-Petersburg
G. N. Salogub
St.-Petersburg State Pavlov Medical University
Russian Federation
Russian Federation
St.-Petersburg
E. R. Machulaitene
St.-Petersburg State Pavlov Medical University
Russian Federation
Russian Federation
St.-Petersburg
E. V. Kariagina
City Hospital 15
Russian Federation
Russian Federation
St.-Petersburg
References
1. Palva P., Ahrenberg P., Ala-Harja K. et al. Treatment of multiple myeloma in old patients. Eur J Haematol 1989; 43: 328–31.
2. Westin J. Conventional chemotherapy in multiple myeloma. Pathol Biol (Paris) 1999; 47: 169–71.
3. Бессмельцев С. С. Множественная миелома. Современный взгляд на проблему / С. С. Бессмельцев, К. М. Абдулкадыров. – Алматы, 2007. – 480 с.
4. Kyle R. A., Rajkumar S. V. Multiple myeloma. Blood 2008; 111 (6): 2962–72.
5. Thomas S., Alexanian R. Current treatment strategies for multiple myeloma. Clin Lymphoma&Myeloma 2007; 7 (Suppl 4): 139–44.
6. Jagannath S., Durie B. G., Wolf J. et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776–83.
7. Greipp P. Treatment paradigms for the newly diagnosed patient with multiple myeloma. Semin Hematol 2005; 42 (Suppl 4): 16–21.
8. Ohashi K. Clinical implications of bortezomib in frontline treatment of newly-diagnosed multiple myeloma. Gan To Kagaku Ryoho 2008; 35: 1029–32.
9. Mateos M. V., Hernández J. M., Hernández M. T. et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008; 93 (4): 560–5.
10. San Miguel J. F., Schlag R., Khuageva N. K. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906–17.
11. Бессмельцев С. С. Бортезомиб (велкейд) в индукционной терапии множественной миеломы / С. С. Бессмельцев [и др.] // Клин. онкогематол. – 2008. – 1 (4): 315–22.
12. Blade J., Samson D., Reece D. et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–23.
13. Бессмельцев С. С. Бортезомиб (велкейд) и дексаметазон в лечении рефрактерных / рецидивирующих форм множественной миеломы (результаты промежуточного анализа) / С. С. Бессмельцев [и др.] // Вестник гематологии. – 2008. – IV (4): 14–22.
14. Бессмельцев С. С. Частота, характеристика и методы лечения периферической нейропатии у больных множественной миеломой, получающих бортезомиб (велкейд) / С. С. Бессмельцев [и др.] // Онкогематология. – 2008. – 3: 52–62.
Review
For citations:
Bessmeltsev S.S., Stelmashenko L.V., Stepanova N.V., Abdulkadyrov K.M., Salogub G.N., Machulaitene E.R., Kariagina E.V. Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma. Oncohematology. 2010;(2):40-45. (In Russ.)
Views:
9053
Email this article 